A new policy brief from the American Economic Liberties Project exposes how for-profit insurers use prior authorization to override physicians and deny necessary medical treatments. Researchers argue this practice—often dubbed a corporate care veto—prioritizes profit margins over patient outcomes, fueling a systemic crisis of delayed and abandoned care.
The report highlights a growing reliance on automated systems and internal review processes that lack transparency. Data from the Commonwealth Fund indicates that one in five privately insured adults faced a coverage denial in the last year, with 28% reporting that the delay directly worsened their health conditions. Physicians report similar frustrations, as 95% state that these administrative hurdles delay essential care, often forcing patients to abandon treatment entirely.
The Human and Financial Toll
The financial implications are equally stark. Researchers estimate that the bureaucratic burden of prior authorization consumes the equivalent of 100,000 full-time physician workloads annually, costing the system roughly $32.7 billion each year. Beyond the numbers, the practice creates a "bureaucratic maze" for families. Report author Hannah Garden-Monheit shared her personal experience, describing how UnitedHealthcare repeatedly denied her father’s rehabilitation claims after an amputation, despite his clear medical necessity.
While insurers defend the practice as evidence-based cost control, critics point to a fundamental conflict of interest. Former United chief medical officer Dr. Archelle Georgiou noted that insurers can save millions annually by denying claims that never face an appeal. The industry is now accelerating this trend by deploying AI models to adjudicate claims en masse, a strategy highlighted by a 2023 class-action lawsuit involving United's NaviHealth system. Despite public support for reform—with two-thirds of voters across party lines favoring a ban—legislative progress remains stalled, leaving patients to navigate a system designed to prioritize corporate savings over clinical judgment.
Comments (0)
No comments yet. Be the first!